<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02888301</url>
  </required_header>
  <id_info>
    <org_study_id>15-000246</org_study_id>
    <secondary_id>NCI-2016-00210</secondary_id>
    <secondary_id>15-000246 2 scan clofarabine</secondary_id>
    <secondary_id>15-000246</secondary_id>
    <secondary_id>P30CA016042</secondary_id>
    <nct_id>NCT02888301</nct_id>
  </id_info>
  <brief_title>18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions</brief_title>
  <official_title>The Biodistribution of [18F]-Clofarabine in Cancer Patients Before and After Interventions That Increase the Activity of Deoxycytidine Kinase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies 18F-clofarabine positron emission tomography (PET)/computed
      tomography (CT) in imaging patients with cancer before and after treatment with a therapy
      that activates the patient's immune system (immunotherapy). PET/CT scans give detailed
      pictures of areas inside the body. 18F-clofarabine is a drug that contains a radioactive
      substance that is taken up by cells expressing deoxycytidine kinase (dCK), which is highly
      expressed in activated immune cells, making them light up during PET/CT scans. Doctors also
      want to know how 18F-clofarabine is distributed throughout the body before and after
      treatment with immunotherapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine whether positron emission tomography (PET) using the new imaging agent
      18F-clofarabine can be used for imaging cancer, and whether interventions that activate the
      immune system can change the biodistribution of 18F-clofarabine.

      OUTLINE:

      Patients receive 18F-clofarabine intravenously (IV) and undergo PET/CT scan at baseline and
      2-4 weeks after completion of immunotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2015</start_date>
  <completion_date type="Anticipated">June 12, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18F-clofarabine concentration in cancer tissue</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 18F-clofarabine biodistribution</measure>
    <time_frame>Baseline to up to 4 weeks</time_frame>
    <description>For the biodistribution studies, regions of interest will be drawn on images of liver, kidney, bladder, heart, lung and blood pool to obtain regional activity count rates. Standardized uptake values (SUV = count activity per ml within region of interest (MBq-1)/(injected dose [MBq]/body weight [kgx1000]) will be calculated for different organs and for regions of tumor. Further, regional target to background count activity ratios will be established.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Basic science (18F-clofarabine biodistribution)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 18F-clofarabine IV and undergo PET/CT scan at baseline and 2-4 weeks after completion of immunotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo 18F-clofarabine PET/CT</description>
    <arm_group_label>Basic science (18F-clofarabine biodistribution)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fluorine F 18 Clofarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Basic science (18F-clofarabine biodistribution)</arm_group_label>
    <other_name>18F-CA</other_name>
    <other_name>18F-Clofarabine</other_name>
    <other_name>[18F]-Clofarabine</other_name>
    <other_name>Cl-18F-ara-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo 18F-clofarabine PET/CT</description>
    <arm_group_label>Basic science (18F-clofarabine biodistribution)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be able to tolerate PET/CT (i.e. not claustrophobic and able to remain supine)

          -  No restrictions based on gender or racial/ethnic background

        Exclusion Criteria:

          -  Women of childbearing age will have to undergo a pregnancy test that will be provided
             free of charge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Allen-Auerbach</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Allen-Auerbach</last_name>
      <phone>310-983-1444</phone>
    </contact>
    <investigator>
      <last_name>Martin Allen-Auerbach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

